Robotic exoskeletons boost stroke recovery with precise

Simple Home Systems Help Reduce Everyday Stress


Reviewing Medications at Home for Safety
Waikato Homes Tackle Dampness, Stale Air with Multi-Pronged Approach
FDA Approves First Gene Therapy for Sanfilippo Syndrome Type A

Breast cancer drug Etcamah fails first-line trial test
Microbiome Diversity
Microbiome Diversity
Microbiome Diversity
Microbiome Diversity 


Group finds Trump drug deals favor drugmakers over patients
Public Citizen scrutinizes the Most-Favoured Nation pricing deals between the Trump administration and 27 pharmaceutical companies, arguing claims...
Three biotech firms eye Nasdaq listings
Three biotech firms—including ADARx Pharma—are preparing Nasdaq listings, with ADARx targeting a $1.74 billion valuation for its hereditary...
Bayer Moves Hyrnuo Into Frontline Lung Cancer
Bayer secured FDA approval for Hyrnuo lung cancer treatment, marking a major shift in frontline HER2-mutant NSCLC care...
Sensorion gets green light for HearConnex trial
Sensorion's HearConnex trial gets green light for hearing loss treatment with gene therapy SENS-601.
Editor's picks
Why Is Medicaid Member Engagement Essential for Health
Medicaid is a cornerstone of healthcare access for millions of Americans, including low-income families, seniors, and individuals with disabilities. While...
Pharma struggles as AI fraud erodes patient trust in calls
AI fraud is eroding patient trust in pharma calls, with scammers using voice cloning and spoofing to mimic legitimate pharmaceutical...
NZ health planners adopt privacy-focused geospatial guidelines
New Zealand health planners are adopting privacy-focused geospatial guidelines to map immunisation rates and service usage while safeguarding location data.
New Zealand expands social prescribing with nine pathways
New Zealand expands social prescribing with nine pathways to address mental health, loneliness, and cost-of-living pressures through community resources.
Hospitals Deploy AI Chatbots to Streamline Pre-Surgery Prep
NZ health planners adopt privacy-focused geospatial guidelines
New Zealand expands social prescribing with nine pathways
Pharma struggles as AI fraud erodes patient trust in calls
All Post
Novo Nordisk drops name to sharpen focus amid Lilly rivalry
Novo Nordisk drops its full name to become 'Novo,' sharpening focus against Eli Lilly in weight loss and diabetes treatments amid slowing growth.
AbbVie tests new approach for menstrual migraine treatment
AbbVie’s Qulipta becomes first oral CGRP inhibitor to succeed in phase 3 menstrual migraine trials, offering hope for resistant cases.
Biotechs lead fight against cancer
Biotechs lead the fight against cancer with next-generation treatments and clinical trials.
Bayer Moves Hyrnuo Into Frontline Lung Cancer
Bayer secured FDA approval for Hyrnuo lung cancer treatment, marking a major shift in frontline HER2-mutant NSCLC care based on new clinical data.
Bristol Myers reports progress in multiple myeloma trial
Bristol Myers reports progress in multiple myeloma trial with arlocabtagene autoleucel showing promise.
Guidelines for e-signature use in global trials
Guidelines for e-signature use in global trials, including qualified e-signature and standard e-signature options.
Ivonescimab Meets Overall Survival Goal in NSCLC
Ivonescimab surpasses Keytruda in overall survival for NSCLC first-line treatment, demonstrating potential breakthrough in lung cancer therapy.
Sensorion gets green light for HearConnex trial
Sensorion's HearConnex trial gets green light for hearing loss treatment with gene therapy SENS-601.
Alumis lupus drug advances after trial setback
Alumis advances its lupus drug to Phase III trials despite mixed Phase IIb results, targeting a specific patient subgroup for better outcomes.
ESC 2026 AstraZeneca oral relaxin passes Phase II
AstraZeneca's AZD5462 shows promise in Phase II trial for chronic heart failure, improving cardiac function via relaxin pathway.